TCGA-A8-A091-01A-11R-A00Z-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 33
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MITOTIC_SPINDLE+0.310
- WNT_BETA_CATENIN_SIGNALING+0.310
- UV_RESPONSE_DN+0.220
- TGF_BETA_SIGNALING+0.190
- HEME_METABOLISM+0.110
- HEDGEHOG_SIGNALING+0.080
- PANCREAS_BETA_CELLS+0.050
- BILE_ACID_METABOLISM+0.020
- PEROXISOME+0.020
- PROTEIN_SECRETION+0.020
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.590
- INTERFERON_GAMMA_RESPONSE-0.530
- TNFA_SIGNALING_VIA_NFKB-0.480
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.410
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.400
- ALLOGRAFT_REJECTION-0.380
- INFLAMMATORY_RESPONSE-0.360
- MYC_TARGETS_V2-0.350
- MTORC1_SIGNALING-0.330
- OXIDATIVE_PHOSPHORYLATION-0.330
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-BL-A0C8-01B-04R-A277-07 | — | — | 0.890 |
| 2 | TCGA-A2-A1FV-01A-11R-A13Q-07 | — | B | 0.864 |
| 3 | TCGA-A8-A09V-01A-11R-A034-07 | — | B | 0.862 |
| 4 | TCGA-A7-A0DC-01B-04R-A22O-07 | — | D | 0.859 |
| 5 | s0102877 | — | — | 0.854 |
| 6 | MDT-AP-3246 | Med | Medulloblastoma | 0.853 |
| 7 | TCGA-OR-A5L8-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.851 |
| 8 | C3N-03420 | — | cohortA1 | 0.847 |
| 9 | SRR8392885 | — | cohortA3 | 0.847 |
| 10 | MNG420 | — | — | 0.846 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MITOTIC_SPINDLE | 0.310 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.310 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.220 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.190 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.110 | Temsirolimus | — uncovered |
| HEDGEHOG_SIGNALING | 0.080 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.050 | Cobimetinib | — uncovered |
| BILE_ACID_METABOLISM | 0.020 | Inavolisib | — uncovered |
| PEROXISOME | 0.020 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.020 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.010 | Inavolisib | — uncovered |